Fig. 4: Roxadustat suppressed chemoresistant GBM growth in vivo and prolonged survival of the GBM mice.

A IVIS images and associated ROI quantification of orthotopic GBM-bearing mice injected with RXD (10 mg/kg) and/or TMZ (35 mg/kg), measured every 7 days (0–21 days). *P < 0.05, **P < 0.01. B The body weight of mice in each group after drug injection was monitored and recorded every 3 days (0–21 days). C The survival curves of orthotopic GBM-bearing mice (n = 5). *P < 0.05, **P < 0.01.